Stopping the itch—new clues into how to treat eczema

October 11, 2012 in Immunology

More than 15% of children suffer with eczema, or atopic dermatitis, an inflammatory skin disease that in some cases can be debilitating and disfiguring. Researchers reporting in the October issue of Immunity have discovered a potential new target for the condition, demonstrating that by blocking it, they can lessen the disease in mice.

In eczema, immune T cells invade the skin and secrete factors that drive an , making the skin itch. Dr. Raif Geha, of Boston Children's Hospital, and his collaborators now show that scratching the skin precipitates the condition by encouraging an influx of other called neutrophils. These neutrophils secrete a lipid called leukotriene B4 that calls in more neutrophils, and more importantly, potent immune T cells that are the hallmark of eczema. These cells cause inflammation that aggravates the skin further. The investigators suspected that blocking the onslaught of these cells might slow down the disease or even stop it in its tracks.

Furthermore, Dr. Geha and his colleagues wondered whether the production of leukotriene B4 served to recruit to the site of mechanical insult. And indeed that was the case. "We showed that a drug that blocks the production of leukotriene B4 blocks the development of inflammation in a mouse model of eczema," says Dr. Geha. His team also found that deleting the receptors on immune cells that bind to leukotriene B4 had a similar effect.

"Our findings suggest that neutrophils play a key role in allergic and that blockade of leukotriene B4 and its receptor might provide a new therapy for eczema," says first author Dr. Michiko Oyoshi.

Most people get eczema as infants, and they tend to outgrow it by adolescence; however some people continue to experience "flare-ups" of an itchy rash on and off throughout life. Some develop these after coming into contact with particular substances, such as specific soaps, or in response to certain conditions, such as a respiratory infection or cold.

More information: Oyoshi et al.: "Leukotriene B4 driven neutrophil recruitment to the skin is essential for allergic skin inflammation." DOI: 10.1016/j.immuni.2012.06.018

Journal reference: Immunity search and more info website

Provided by Cell Press search and more info website

5 /5 (2 votes)  

Rank 5 /5 (2 votes)
Related Stories
Relevant PhysicsForums posts

More news stories

New immune system discovered

(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.

Immunology created May 20, 2013 | popularity 4.8 / 5 (21) | comments 8 | with audio podcast

Vitamin D could provide new and effective treatments for asthma

(Medical Xpress)—Scientists at King's College London have discovered that Vitamin D has the potential to significantly reduce the symptoms of asthma. The study, led by Professor Catherine Hawrylowicz from ...

Immunology created May 20, 2013 | popularity 5 / 5 (1) | comments 0 | with audio podcast

Immune protein could stop diabetes in its tracks

Melbourne researchers have identified an immune protein that has the potential to stop or reverse the development of type 1 diabetes in its early stages, before insulin-producing cells have been destroyed.

Immunology created May 20, 2013 | popularity 5 / 5 (5) | comments 0 | with audio podcast

Stem-cell-based strategy boosts immune system in mice

Raising hopes for cell-based therapies, UC San Francisco researchers have created the first functioning human thymus tissue from embryonic stem cells in the laboratory. The researchers showed that, in mice, ...

Immunology created May 16, 2013 | popularity 4.8 / 5 (5) | comments 0 | with audio podcast

Resistance to visceral leishmaniasis: New mechanisms involved

Researchers from CNRS, Université Toulouse III - Paul Sabatier and IRD have elucidated new molecular mechanisms involved in resistance to visceral leishmaniasis, a serious parasitic infection. They have shown that dectin-1 ...

Immunology created May 16, 2013 | popularity not rated yet | comments 0


If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

Insight into the dazzling impact of insulin in cells

Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.

Antidepressant reduces stress-induced heart condition

A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.